抗血小板治疗与动脉瘤性蛛网膜下腔出血后迟发性脑缺血:系统综述与Meta分析
该系统综述与Meta分析纳入15项研究共2039例动脉瘤性蛛网膜下腔出血患者,比较抗血小板治疗与未抗血小板治疗的结局。抗血小板治疗组迟发性脑缺血、血管造影及症状性血管痉挛、院内死亡和功能依赖发生率均较低,出血事件率两组相当。作者认为研究异质性是最主要局限,抗血小板治疗值得在随机对照试验中探索。
要点
- 抗血小板治疗组迟发性脑缺血汇总发生率15.9% vs 未抗血小板组28.6%(OR 0.47,p<0.01)。
- 抗血小板治疗组出血事件率与未抗血小板组相当。
- 西洛他唑单药亚组迟发性脑缺血汇总发生率10.6% vs 未抗血小板组28.1%(OR 0.31,p<0.01)。
核心结论
- 抗血小板治疗与动脉瘤性蛛网膜下腔出血患者结局改善相关,且不增加出血事件风险,尤其在行动脉瘤手术修复及接受西洛他唑治疗的患者中。
- 尽管研究异质性是该分析最主要的局限性,作者认为抗血小板治疗值得在动脉瘤性蛛网膜下腔出血患者中探索,特别是在随机对照试验背景下。
研究设计与样本
- 系统综述与Meta分析,检索PubMed和MEDLINE数据库。
- 纳入标准为:动脉瘤性蛛网膜下腔出血患者≥5例;直接比较抗血小板治疗与未抗血小板治疗;报告抗血小板治疗与未抗血小板治疗患者的迟发性脑缺血、血管造影或症状性血管痉挛发生率。
- 总队列纳入15项研究共2039例患者,主要疗效结局为迟发性脑缺血,采用Downs and Black清单评估偏倚。
主要发现
- 迟发性脑缺血在抗血小板治疗组较未抗血小板组更少见(汇总15.9% vs 28.6%;OR 0.47,p<0.01)。
- 血管造影性血管痉挛率抗血小板治疗组低于未抗血小板组(汇总51.6% vs 68.7%;OR 0.46,p<0.01),症状性血管痉挛率亦较低(汇总23.6% vs 37.7%;OR 0.51,p=0.01)。
- 院内死亡率抗血小板治疗组低于未抗血小板组(汇总1.7% vs 4.1%;OR 0.53,p=0.01),功能依赖率亦较低(汇总21.0% vs 35.7%;OR 0.53,p<0.01)。
- 出血事件率两组相当。
- 西洛他唑单药与未抗血小板治疗比较的亚组分析显示西洛他唑组迟发性脑缺血率较低(汇总10.6% vs 28.1%;OR 0.31,p<0.01);手术治疗的动脉瘤亚组分析显示抗血小板治疗组迟发性脑缺血率较低(汇总18.4% vs 33.9%;OR 0.43,p=0.02)。
临床怎么用
- 作者认为抗血小板治疗值得在动脉瘤性蛛网膜下腔出血患者中探索,特别是在随机对照试验背景下。
局限性
- 研究异质性是该分析最主要的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Delayed cerebral ischemia (DCI) is a potentially preventable cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (aSAH). The authors performed a meta-analysis to assess the effect of antiplatelet therapy (APT) on DCI in patients with aSAH. METHODS: A systematic review of the PubMed and MEDLINE databases was performed. Study inclusion criteria were 1) ≥ 5 aSAH patients; 2) direct comparison between aSAH management with APT and without APT; and 3) reporting of DCI, angiographic, or symptomatic vasospasm rates for patients treated with versus without APT. The primary efficacy outcome was DCI. The outcomes of the APT versus no-APT cohorts were compared. Bias was assessed using the Downs and Black checklist. RESULTS: The overall cohort comprised 2039 patients from 15 studies. DCI occurred less commonly in the APT compared with the no-APT cohort (pooled = 15.9% vs 28.6%; OR 0.47, p < 0.01). Angiographic (pooled = 51.6% vs 68.7%; OR 0.46, p < 0.01) and symptomatic (pooled = 23.6% vs 37.7%; OR 0.51, p = 0.01) vasospasm rates were lower in the APT cohort. In-hospital mortality (pooled = 1.7% vs 4.1%; OR 0.53, p = 0.01) and functional dependence (pooled = 21.0% vs 35.7%; OR 0.53, p < 0.01) rates were also lower in the APT cohort. Bleeding event rates were comparable between the two cohorts. Subgroup analysis of cilostazol monotherapy compared with no APT demonstrated a lower DCI rate in the cilostazol cohort (pooled = 10.6% vs 28.1%; OR 0.31, p < 0.01). Subgroup analysis of surgically treated aneurysms demonstrated a lower DCI rate for the APT cohort (pooled = 18.4% vs 33.9%; OR 0.43, p = 0.02). CONCLUSIONS: APT is associated with improved outcomes in aSAH without an increased risk of bleeding events, particularly in patients who underwent surgical aneurysm repair and those treated with cilostazol. Although study heterogeneity is the most significant limitation of the analysis, the findings suggest that APT is worth exploring in patients with aSAH, particularly in a randomized controlled trial setting.
引用
- Snyder MH, Ironside N, Kumar JS, et al. Antiplatelet therapy and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurosurg. 2021. PMID: 34740185. doi:10.3171/2021.7.JNS211239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。